|
Each year, ESMO hosts a conference where cutting-edge research across all cancer types is presented, including critical updates in kidney cancer.
The International Kidney Cancer Coalition (IKCC), a global network of patient advocacy groups like KidneyCAN, reviews the kidney cancer research presented at ESMO and compiles key highlights.
This year’s updates include promising new treatments like belzutifan, a HIF-2α inhibitor, which showed improved outcomes for patients with advanced kidney cancer, and ongoing studies like the SUNNIFORECAST trial exploring better treatment options for non-clear cell kidney cancers.
Stay informed with the full ESMO highlights:
|